Stocktoria
Spero Therapeutics, Inc. SPRO
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2017-11-02
Chart by TradingView
4/9
Piotroski F — financial health
-8.9
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | $66.8M | $48.0M | $933,000 | $53.5M | $3.1M |
| Operating income | $6.3M | -$73.4M | $21.5M | -$42.2M | -$88.0M |
| Net income | $8.6M | -$68.6M | $22.8M | — | -$89.8M |
| Operating cash flow | -$12.6M | -$23.4M | -$33.0M | -$7.7M | -$64.3M |
| Total assets | $68.9M | $110.5M | $182.4M | $124.8M | $171.1M |
| Total liabilities | $9.9M | $64.4M | $75.5M | $48.9M | $82.8M |
| Shareholders' equity | $59.0M | $46.1M | $106.9M | $75.9M | $88.3M |
| Ratios | |||||
| Operating margin | 9.5% | -152.9% | 2302.4% | -78.9% | -2865.5% |
| Net margin | 12.8% | -142.9% | 2444.4% | — | -2925.1% |
| Return on assets | 12.4% | -62.0% | 12.5% | — | -52.5% |
| Return on equity | 14.5% | -148.7% | 21.3% | — | -101.7% |
| Current ratio | 7.59 | 2.19 | 3.53 | 5.25 | 8.46 |
| Revenue growth | 39.2% | 5042.2% | -98.3% | 1643.0% | 1089.9% |
Notable holders (13F)
| Investor | Shares | Value |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | 1,189,235 | $2.8M |
| Point72 Asset Management, L.P. | 59,668 | $139,623 |
Why these scores methodology →
Piotroski F-score: 4/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -8.9 (distress)
- Working capital / assets 0.848
- Retained earnings / assets -6.545
- EBIT / assets 0.092
- Equity / liabilities 5.963
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001701108 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.